Credit Suisse’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-6,300
Closed -$167K 3817
2021
Q4
$167K Sell
6,300
-42,100
-87% -$1.45M ﹤0.01% 4318
2021
Q3
$1.99M Sell
48,400
-87,200
-64% -$4.78M ﹤0.01% 2823
2021
Q2
$7.68M Buy
135,600
+48,200
+55% +$1.78M ﹤0.01% 1743
2021
Q1
$3.67M Buy
+87,400
New +$4.98M ﹤0.01% 2334

Other funds holding EDIT

Credit Suisse's EDIT Position: Q1 2024 in Review

Credit Suisse increased its Editas Medicine (EDIT) stake by 0.76% in Q1 2024, buying an estimated $56.3K and bringing the position to 903,257 shares worth $6.7M. The position accounts for 0.01% of the portfolio, ranked #1139.

Credit Suisse first reported a position in EDIT in Q3 2016 and has held it in 31 quarters since. The position peaked at $59.5M in Q4 2020. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • Credit Suisse held 903,257 shares of Editas Medicine worth $6.7M as of Q1 2024.
  • Credit Suisse bought 6,781 Editas Medicine shares in Q1 2024, an estimated $56.3K.
  • Editas Medicine made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1139 holding.
  • Credit Suisse first reported a position in Editas Medicine in Q3 2016 and has held it in 31 quarters since.
  • Credit Suisse's Editas Medicine position peaked at $59.5M in Q4 2020.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.